Intricate Interplay between Innate Immune Cells and TRMP2 in a Mouse Model of Multiple Sclerosis

Caravagna, Céline

doi:10.1523/jneurosci.2982-18.2019

Cited by 1 publication

(2 citation statements)

References 18 publications

(19 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Due to the heterogeneity of disease course and therapeutic responses in different patients with MS, the best intervention timepoint, the feasible combination therapeutics regimens and selective patients who may benefit from PD-1/PD-L1-based therapies should be confirmed to achieve an optimized therapeutic outcome. [3] PD-1/PD-L1 therapies used for alleviate neuroinflammation must have superior bioavailability across the BBB. The ideal carrier can overcome the obstacles and deliver PD-1/PD-L1-based drugs into the CNS.…”

Section: Concluding Remarks and Future Directionsmentioning

confidence: 99%

“…Genetic predisposition, epigenetic factors, lifestyle, and environmental factors all contribute to the risk of MS [1]. Previous studies indicated the immune dysfunction playing a primary role in the pathogenesis of MS [2][3][4]. Various types of immune cells including T cells, B cells, natural killer (NK) cells, dendritic cells (DCs), and macrophages/microglia are involved in the disease course [5].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Role of the PD‐1/PD‐L1 Signaling in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis: Recent Insights and Future Directions

Han

Zhu

et al. 2021

Mol Neurobiol

View full text Add to dashboard Cite

Multiple sclerosis (MS) is an autoimmunity-related chronic demyelination disease of the central nervous system (CNS), causing young disability. Currently, highly specific immunotherapies for MS are still lacking. Programmed cell death 1 (PD-1) is an immunosuppressive co-stimulatory molecule, which is expressed on activated T lymphocytes, B lymphocytes, natural killer cells, and other immune cells. PD-L1, the ligand of PD-1, is expressed on T lymphocytes, B lymphocytes, dendritic cells, and macrophages. PD-1/PD-L1 delivers negative regulatory signals to immune cells, maintaining immune tolerance and inhibiting autoimmunity. This review comprehensively summarizes current insights into the role of PD-1/PD-L1 signaling in MS and its animal model experimental autoimmune encephalomyelitis (EAE). The potentiality of PD-1/PD-L1 as biomarkers or therapeutic targets for MS will also be discussed.

show abstract

Section: Concluding Remarks and Future Directionsmentioning

confidence: 99%